Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NRXP

NRX Pharmaceuticals Inc

Jan 24 • 04:00PM ET

3.22

Dollar change +0.29
Percentage change 9.90	%

Healthcare • Biotechnology • USA • NASD

Peers: LGND ARDX FGEN DVAX BCRX GERN ALDX ANVS APVO CRBP

| Held by: PSIL VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.15	Insider Own	23.89%	Shs Outstand	11.37M	Perf Week	-24.41%
Market Cap	38.94M	Forward P/E	10.06	EPS next Y	0.32	Insider Trans	1.40%	Shs Float	9.20M	Perf Month	114.67%
Income	-20.39M	PEG	-	EPS next Q	-0.32	Inst Own	5.91%	Short Float	6.99%	Perf Quarter	168.33%
Sales	0.00M	P/S	-	EPS this Y	53.58%	Inst Trans	38.81%	Short Ratio	0.59	Perf Half Y	32.51%
Book/sh	-1.65	P/B	-	EPS next Y	117.24%	ROA	-231.96%	Short Interest	0.64M	Perf Year	-23.33%
Cash/sh	0.14	P/C	23.60	EPS next 5Y	-	ROE	-	52W Range	1.10 - 7.33	Perf YTD	46.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-56.09%	Beta	1.14
Dividend TTM	-	Quick Ratio	0.20	Sales past 5Y	0.00%	Gross Margin	-	52W Low	192.73%	ATR (14)	0.65
Dividend Ex-Date	-	Current Ratio	0.20	EPS Y/Y TTM	57.84%	Oper. Margin	-	RSI (14)	51.79	Volatility	17.87% 28.55%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	31.67
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	80.01%	Payout	-	Rel Volume	0.59	Prev Close	2.93
Sales Surprise	-	EPS Surprise	72.97%	Sales Q/Q	-	Earnings	Nov 18 AMC	Avg Volume	1.09M	Price	3.22
SMA20	-3.49%	SMA50	52.84%	SMA200	38.07%	Trades		Volume	642,936	Change	9.90%

Jan-21-25 08:02AM	NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement (PR Newswire) -11.97%
Jan-15-25 08:02AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc. (PR Newswire) -11.96%
Jan-14-25 08:03AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel (PR Newswire)
Jan-13-25 08:04AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market (PR Newswire)
Jan-10-25 08:04AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago Club (PR Newswire) +28.99%
10:20AM	Loading…
Jan-08-25 10:20AM	Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region (GlobeNewswire) -19.31%
Jan-07-25 08:07AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco (PR Newswire) +32.76%
Jan-06-25 10:16AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations (PR Newswire) +30.48%
08:03AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics (PR Newswire)
Jan-03-25 08:03AM	HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025 (PR Newswire) -10.03%
Jan-02-25 08:03AM	Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics (PR Newswire) +35.91%
Dec-30-24 08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression (PR Newswire)
Nov-26-24 08:03AM	NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024 (PR Newswire)
Nov-25-24 08:03AM	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled 'Quality Assurance of Depression Ratings in Psychiatric Clinical Trials' (PR Newswire)
Nov-19-24 02:03AM	NRX Pharmaceuticals Inc (NRXP) Q3 2024 Earnings Call Highlights: Significant Reduction in ... (GuruFocus.com) -5.77%
04:05PM	Loading…
Nov-18-24 04:05PM	NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer (PR Newswire) +9.24%
Nov-14-24 04:05PM	NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update (PR Newswire) -7.20%
Nov-13-24 08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 (PR Newswire)
Nov-07-24 04:06PM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024 (PR Newswire)
Oct-31-24 07:00AM	NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule (GlobeNewswire)
Oct-30-24 07:47AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics (PR Newswire) +12.60%
Oct-23-24 08:30AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 (GlobeNewswire)
Oct-12-24 05:18PM	NRx Pharmaceuticals Leadership Shift and Strategic Governance Decisions (TipRanks)
Oct-03-24 06:55AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic (PR Newswire)
Sep-30-24 07:00AM	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine) (PR Newswire)
Sep-11-24 07:55AM	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com (PR Newswire)
Sep-03-24 07:55AM	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 (PR Newswire) -12.03%
Aug-26-24 07:55AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics (PR Newswire) -9.13%
Aug-14-24 04:01PM	NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update (PR Newswire) -6.45%
Aug-13-24 04:01PM	NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024 (PR Newswire) -7.31%
07:30AM	Loading…
07:30AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds (PR Newswire)
Jul-29-24 08:35AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine) (PR Newswire)
08:30AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals (Nasdaq:NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff (PR Newswire)
Jul-01-24 08:07AM	NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter (PR Newswire) +5.74%
Jun-28-24 08:07AM	NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing (PR Newswire) -6.87%
Jun-20-24 08:30AM	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 (PR Newswire)
Jun-18-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors (PR Newswire)
Jun-10-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter (PR Newswire)
May-28-24 08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression (PR Newswire)
May-14-24 08:57PM	NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace) +6.35%
04:01PM	NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-08-24 09:55AM	NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update (ACCESSWIRE)
08:30AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024 (PR Newswire)
May-07-24 04:01PM	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024 (PR Newswire) -8.17%
May-06-24 08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression (PR Newswire) +45.71%
Apr-30-24 08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression (PR Newswire) -27.32%
Apr-18-24 08:56AM	Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today? (InvestorPlace) -27.75%
08:32AM	NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement (PR Newswire)
08:30AM	NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock (PR Newswire)
Apr-17-24 04:45PM	NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire)
08:30AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections (PR Newswire)
Apr-15-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) (PR Newswire)
Apr-08-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression (PR Newswire)
Apr-04-24 12:00PM	NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +9.70%
Apr-02-24 10:33AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-01-24 08:28AM	NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (PR Newswire) +11.25%
Mar-28-24 10:53PM	NRXP Stock Earnings: NRX Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace) -10.96%
08:03AM	NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights (PR Newswire)
08:00AM	NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing (PR Newswire)
Mar-26-24 04:03PM	UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 (PR Newswire)
Mar-25-24 08:30AM	NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK (PR Newswire) -5.36%
Mar-21-24 04:02PM	NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024 (PR Newswire) +10.87%
01:57PM	NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders (PR Newswire)
Mar-18-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders (PR Newswire) +13.16%
Mar-12-24 07:49AM	NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales (PR Newswire) -34.32%
Mar-11-24 08:30AM	NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) (PR Newswire) +9.06%
Mar-04-24 08:30AM	NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression (PR Newswire) +18.69%
Mar-01-24 08:30AM	NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share (PR Newswire) +22.03%
Feb-27-24 10:49AM	/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./ (PR Newswire) -31.24%
08:54AM	NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 million (PR Newswire)
08:31AM	Why Is NRX Pharmaceuticals (NRXP) Stock Down 23% Today? (InvestorPlace)
Feb-26-24 04:01PM	NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire)
08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024 (PR Newswire)
Feb-20-24 08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024 (PR Newswire)
Feb-12-24 08:30AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW) (PR Newswire) -6.25%
Feb-09-24 08:30AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report (PR Newswire) +10.34%
Feb-05-24 06:48AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon (PR Newswire) +5.28%
Jan-22-24 06:48AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression (PR Newswire)
Jan-17-24 06:48AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination (PR Newswire)
Jan-16-24 06:48AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis (PR Newswire)
Jan-02-24 08:45AM	NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco (PR Newswire) +8.48%
06:48AM	NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard (PR Newswire)
Dec-27-23 06:48AM	NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors (PR Newswire)
Dec-19-23 08:15AM	NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression (PR Newswire) -7.34%
Dec-18-23 06:48AM	NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections (PR Newswire) +24.19%
Dec-13-23 04:02PM	NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders (PR Newswire)
Dec-11-23 06:48AM	NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event (PR Newswire)
Nov-27-23 04:01PM	NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference (PR Newswire)
Nov-16-23 02:07PM	NRx Pharmaceuticals founder unveils potential treatment for suicidal thoughts and depression (News Direct) -6.86%
09:32AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 06:39PM	NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-07-23 06:48AM	NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023 (PR Newswire)
Nov-06-23 06:48AM	NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression (PR Newswire) +5.22%
Oct-31-23 06:48AM	NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression (PR Newswire)
Oct-26-23 06:48AM	NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain (PR Newswire) +6.71%
Oct-12-23 06:48AM	NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference (PR Newswire) +6.54%
Oct-05-23 06:48AM	NRx Pharmaceuticals to Present at 8th Annual Dawson James Conference (PR Newswire)
Oct-02-23 06:48AM	NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain (PR Newswire) +10.42%
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-20-23 06:47AM	NRx Pharmaceuticals Publishes Shareholder Update Letter (PR Newswire)

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Javitt Jonathan C	Chairman and Chief Scientist	Dec 17 '24	Buy	1.17	40,000	46,800	84,634	Dec 18 08:27 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRXP

NRX Pharmaceuticals Inc

Upgrade your FINVIZ experience